Open AccessAn open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
Author(s) -
Walter Fiedler,
Pau Montesinos,
Christoph Schliemann,
Jan Moritz Middeke,
Sumithira Vasu,
Christian W. Scholz,
Jordi Esteve,
Shoubhik Mondal,
Björn Rüter,
Ute Burkard,
Annika Osswald,
William Blum
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2022.281128
Subject(s) - pharmacokinetics , decitabine , medicine , open label , maximum tolerated dose , pharmacology , monoclonal antibody , oncology , clinical trial , antibody , chemistry , immunology , biochemistry , gene expression , dna methylation , gene